Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

Video

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Ankit Kansagra, MD, assistant professor, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

CAR T-cell therapy has shown unprecedented activity in multiple myeloma, explains Kansagra.

Combining CAR T-cell therapy with other drugs may improve T-cell persistence; however, investigational combinations are still in preclinical stages of research, says Kansagra. CAR T-cell therapy could also show enhanced responses earlier on in treatment. As such, several trials are evaluating CAR T-cell therapy in the early relapse setting rather than in heavily pretreated patient populations.

Furthermore, little is known about the optimal treatment for patients who progress on CAR T-cell therapy. This is an area of unmet need that requires further investigation, concludes Kansagra.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.